X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis

By Stephen J. Ubl  |    March 31, 2021
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections....   Read More

Data shows that keeping a strong biopharmaceutical industry is important to Americans

By Mark Keida  |    March 30, 2021
The United States biopharmaceutical industry continues to innovate and discover critical solutions for our toughest health challenges such as the COVID-19 pandemic. America’s global leadership has...   Read More

New report demonstrates the growing importance of partnerships in advancing biomedical innovation

By Abigail Lore  |    March 24, 2021
As we mark a full year since COVID-19 was declared a global pandemic, it’s impossible to overstate the significance of collaborations. The unprecedented level of strategic collaborative efforts...   Read More

Cross-country comparisons of medicine prices are like comparing apples to oranges

By Nicole Longo  |    March 22, 2021
Looking at differences in medicine prices between the United States and other countries can be misleading, often ignoring the complexities in the U.S. system and the repercussions of other...   Read More

Building confidence in the COVID-19 vaccine through education

By Megan Van Etten  |    March 22, 2021
Throughout the COVID-19 vaccine research and development process, the biopharmaceutical industry has worked to uphold the highest standards of research, clinical testing and manufacturing.   Read More

ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy

By Tom Wilbur  |    March 11, 2021
On January 19, 2021 – the last full day of the Trump administration – CMS released a Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This model would...   Read More

Getting the 340B program back on track in 2021

By Nicole Longo  |    March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...   Read More

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines

By Andrew Powaleny  |    March 8, 2021
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress   Read More

Intellectual property is the key to vaccine development, manufacturing and technology sharing

By Megan Van Etten  |    March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...   Read More

Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive

By Abigail Lore  |    March 5, 2021
Last week, PhRMA submitted comments to the United States Patent and Trademark Office (USPTO) in response to a request for comments on the National Strategy for Expanding American Innovation....   Read More

How industry collaboration and partnerships are supporting COVID-19 vaccine manufacturing

By Richard Moscicki, M.D.  |    March 4, 2021
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Companies are working to source needed raw materials and other...   Read More

Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter

By Katie Koziara  |    March 2, 2021
A new study published in Health Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates